RNA-Targeting Therapies for Neurodegenerative Diseases

RNA-Targeting Therapies for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RNA-Targeting Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Gene-Silencing Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>mRNA of disease-causing genes</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to FDA-Approved</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>SOD1</td>
</tr>
<tr>
<td class="label">Nusinersen</td>
<td>SMN2</td>
</tr>
<tr>
<td class="label">Inotersen</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">Patisiran</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ASO-[C9orf72](/entities/c9orf72)</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">ASO-GRN</td>
<td>GRN</td>
</tr>
<tr>
<td class="label">ASO-SNCA</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">ASO-[HTT](/genes/htt)</td>
<td>HTT</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[MAPT](/proteins/mapt-protein)</td>
</tr>
</table>

Introduction

...

RNA-Targeting Therapies for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RNA-Targeting Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Gene-Silencing Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>mRNA of disease-causing genes</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to FDA-Approved</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>SOD1</td>
</tr>
<tr>
<td class="label">Nusinersen</td>
<td>SMN2</td>
</tr>
<tr>
<td class="label">Inotersen</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">Patisiran</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ASO-[C9orf72](/entities/c9orf72)</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">ASO-GRN</td>
<td>GRN</td>
</tr>
<tr>
<td class="label">ASO-SNCA</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">ASO-[HTT](/genes/htt)</td>
<td>HTT</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[MAPT](/proteins/mapt-protein)</td>
</tr>
</table>

Introduction

Rna Targeting Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

RNA-targeting therapies represent a revolutionary approach to treating neurodegenerative diseases by directly targeting the messenger RNA (mRNA) that produces toxic proteins. By reducing the production of disease-causing proteins at their source, these therapies offer the potential for disease modification rather than just symptom management. [@rna2024]

Mechanism of Action

Antisense Oligonucleotides (ASOs)

• Single-stranded DNA analogs that bind to complementary target mRNA
• RNase H-mediated degradation: ASO-RNA hybrid recruits RNase H to cleave the RNA
• Splice-modulating ASOs: Alter RNA splicing to exclude toxic exons
• Steric blockade: Block translation or splicing without degrading mRNA

RNA Interference (RNAi)

• Small interfering RNAs (siRNAs): 21-23 nucleotide double-stranded RNAs
• Short hairpin RNAs (shRNAs): Hairpin structures processed into siRNAs
• MicroRNA (miRNA) mimics/antagonists: Modulate endogenous miRNA function
• Argonaute-containing silencing complexes mediate gene silencing

Small Molecule RNA Modulators

• RNA splice modifiers: Small molecules that modulate splicing
• RNA-binding protein modulators: Target proteins that regulate RNA metabolism
• Ribonucleotide reductase inhibitors: Affect RNA synthesis

Approved and Clinical-Stage Therapies

FDA-Approved ASOs

In Clinical Development

Disease-Specific Applications

ALS

• SOD1 ASOs (Tofersen): Reduce SOD1 protein in SOD1-linked ALS
• C9orf72 ASOs: Target hexanucleotide repeat expansions
• ATXN2 ASOs: Reduce ataxin-2 levels (ALS risk factor)
• FUS ASOs: Target FUS protein aggregation

Alzheimer's Disease

• [BACE1](/entities/bace1) ASOs: Reduce BACE1 enzyme to lower [Aβ](/proteins/amyloid-beta) production
• Tau ASOs: Target [MAPT](/genes/mapt) mRNA to reduce tau
• [APOE](/proteins/apoe-protein) ASOs: Target APOE4 allele expression
• SNCA ASOs: Reduce [α-synuclein](/proteins/alpha-synuclein) for DLB

Parkinson's Disease

• SNCA ASOs: Direct targeting of α-synuclein
• LRRK2 ASOs: Target LRRK2 mutations
• GBA ASOs: Modulate glucocerebrosidase expression

Huntington's Disease

• HTT ASOs: Lower mutant [huntingtin protein](/proteins/huntingtin-protein) (several in trials)
• Allele-selective ASOs: Target mutant HTT while sparing wild-type
• Splice-modulating ASOs: Exclude exon 1 to reduce toxic fragments

FTD/ALS Spectrum

• GRN ASOs: Reduce progranulin for GRN mutations
• C9orf72 ASOs: Target repeat expansions
• MAPT ASOs: Reduce tau for CBD/PSP

Delivery Challenges

Blood-Brain Barrier Penetration

• Intrathecal delivery: Direct to CSF (used for nusinersen, tofersen)
• Conjugated ASOs: Using receptor-mediated transcytosis
• AAV-delivered RNAi: Gene therapy approach
• Intranasal delivery: Non-invasive alternative

Cellular Uptake

• Naked ASOs: Rely on endocytosis
• Conjugated ASOs: Enhance cellular entry
• Formulation with lipids: Improve delivery
• Viral vectors: For shRNA/miRNA delivery

Adverse Effects

ASO-Related

• Injection site reactions (for intrathecal delivery)
• Thrombocytopenia
• Liver enzyme elevations
• Kidney toxicity
• CSF pleocytosis (mild inflammation)

RNAi-Related

• Off-target effects: Unintended gene silencing
• Immune activation: Cytokine responses to dsRNA
• Delivery-related: Inflammation at injection site

Research Directions

Allele-Selective Therapy: Targeting mutant allele while sparing wild-type

Motor Neuron-Targeting: Improving delivery to motor [neurons](/entities/neurons)

Combination Approaches: ASO + small molecule combinations

Biomarkers: Developing PK/PD markers for clinical trials

Repeat-Expansion Targeting: Beyond C9orf72 (SCA, HD)

Non-Viral Delivery: Safer than viral vectors

See Also

• [Gene Therapy for Neurodegenerative Diseases](/gene-therapy-for-neurodegenerative-diseases)
• [Antisense Oligonucleotide Therapy](/therapeutics/antisense-oligonucleotide-therapy)
• [RNA Metabolism Dysregulation Pathway](/mechanisms/rna-metabolism-dysregulation)
• [SOD1 in ALS Pathway](/sod1-als-pathway)
• [C9orf72 Dipeptide Repeat Pathway](/mechanisms/c9orf72-pathway)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Rna Targeting Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Investment Landscape

For detailed investment analysis, clinical trial pipeline, and key player profiles, see [RNA Therapeutics: Investment Landscape Analysis](/rna-therapeutics:-investment-landscape-analysis).

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Miller T, et al, Phase 1-2 trial of tofersen for SOD1 ALS (2020)

[^2] Tabrizi SJ, et al, Targeting huntingtin for Huntington's disease (2019)

[^3] Benn CL, et al, ASO approaches for neurodegenerative diseases (2021)

[^4] Nguyen L, et al, RNA-targeting therapies for ALS and FTD (2023)

[^5] Southwell AL, et al, Huntingtin lowering for Huntington's disease (2022)

[^6] Swayze EE, et al, Antisense oligonucleotides targeting disease-associated proteins (2022)

[^7] Bhattacharya K, et al, siRNA delivery to the brain: progress and challenges (2021)

[^8] Khvorova A, et al, RNA targeting in neurological disease (2024)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
• [Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BACE1
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA

Related Analyses:

• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;